Scholarlink

Background/objective <p>Crohn’s Disease (CD) is a chronic inflammatory bowel disease that affects micronutrient levels, impacting metabolic pathways. Homocysteine (Hcy) levels, regulated by folate and vitamin B12, are associated with cardiovascular and extraintestinal manifestations (EIMs). This study aims to analyze the dietary intake and serum concentrations of folate and vitamin B12 and their relationship with systemic complications in patients with CD in remission and active phases.</p> Methods <p>This cross-sectional study included 60 patients, and nutrient intake was stratified into tertiles by disease phase. The metabolic safety of folate and B12 was evaluated by characterizing metabolic risk patterns associated with elevated Hcy. Statistical analyses evaluated associations between dietary intake, metabolic safety, and disease phenotype.</p> Results <p>Vitamin B12 intake was negatively associated with erythrocyte sedimentation rate and positively associated with the absence of EIMs. Serum folate and non-HDL cholesterol levels were lower in the active group. Clinical vitamin B12 deficiency was more frequent in active disease, contributing to an elevated Hcy risk. Stricturing/penetrating phenotypes showed lower vitamin B12 levels compared to non-stricturing, non-penetrating phenotypes. Additionally, 96% of patients with structuring/penetrating disease were at high Hcy risk, while 30% of patients with non-stricturing, non-penetrating disease were in the lowest risk category.</p> Conclusions <p>The data suggest that folate and B12 levels could be markers for clinical characteristics and associated metabolic risk in patients with CD. Our study highlighted associations that may justify the importance of nutritional follow-up and biochemical assessments in the clinical routine of patients with CD.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of serum and dietary profiles of vitamin B12 and folate and their association with systemic complications in patients with Crohn’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月27日

查看全文
  • Marina Moreira de Castro,
  • Vitor Nascimento dos Santos,
  • Maysa Santos Gomes,
  • Aline Dias Gonçalves Ferraz,
  • Leticia Martins Ignacio-Souza,
  • Marcio Alberto Torsoni,
  • Adriana Souza Torsoni,
  • Maria de Lourdes Setsuko Ayrizono,
  • Raquel Franco Leal,
  • Ligiana Pires Corona,
  • Marciane Milanski

摘要

Background/objective

Crohn’s Disease (CD) is a chronic inflammatory bowel disease that affects micronutrient levels, impacting metabolic pathways. Homocysteine (Hcy) levels, regulated by folate and vitamin B12, are associated with cardiovascular and extraintestinal manifestations (EIMs). This study aims to analyze the dietary intake and serum concentrations of folate and vitamin B12 and their relationship with systemic complications in patients with CD in remission and active phases.

Methods

This cross-sectional study included 60 patients, and nutrient intake was stratified into tertiles by disease phase. The metabolic safety of folate and B12 was evaluated by characterizing metabolic risk patterns associated with elevated Hcy. Statistical analyses evaluated associations between dietary intake, metabolic safety, and disease phenotype.

Results

Vitamin B12 intake was negatively associated with erythrocyte sedimentation rate and positively associated with the absence of EIMs. Serum folate and non-HDL cholesterol levels were lower in the active group. Clinical vitamin B12 deficiency was more frequent in active disease, contributing to an elevated Hcy risk. Stricturing/penetrating phenotypes showed lower vitamin B12 levels compared to non-stricturing, non-penetrating phenotypes. Additionally, 96% of patients with structuring/penetrating disease were at high Hcy risk, while 30% of patients with non-stricturing, non-penetrating disease were in the lowest risk category.

Conclusions

The data suggest that folate and B12 levels could be markers for clinical characteristics and associated metabolic risk in patients with CD. Our study highlighted associations that may justify the importance of nutritional follow-up and biochemical assessments in the clinical routine of patients with CD.